[Department of Error] Department of Error
Jørgensen KK, Olsen IC, Goll GL, et al, on behalf of the NOR-SWITCH study group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017; 389: 2304–2316—In figure 2 of this Article, the upper limit of the 95% CI for overall risk difference should have been “3·9”. The appendix has also been replaced. These corrections have been made to the online version as of May 23, 2017, and the printed Article is correct.